Study identification

EU PAS number

EUPAS1000000068

Study ID

1000000068

Official title and acronym

Effectiveness of SGLT2 Inhibitors in Patients With Heart Failure: Real-World Cohort Study.

DARWIN EU® study

No

Study countries

France

Study description

This study will use real-world data from the French National Health Database SNDS spanning from 2021 to 2023 to evaluate the effectiveness of SGLT-2 inhibitors in heart failure. Participants will be identified based on their initial heart failure related hospitalization. Two groups will be established: one exposed to SGLT-2 inhibitors and one not exposed. Patients will be matched based on propensity scores. The study will assess outcomes including hospitalizations related to heart failure and overall mortality.

Study status

Planned
Research institutions and networks

Institutions

Contact details

Paul Gautier 0009-0008-9934-8432

Primary lead investigator
ORCID number:
0009-0008-9934-8432

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Other public funding (e.g. hospital or university)

More details on funding

P.G. received a grant from the Fédération Française de Cardiologie for the academic year 2023-2024.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable